Skip to main content
PMC home page
Frontiers in Physiology logoLink to Frontiers in Physiology
. 2017 Dec 18;8:1081. doi: 10.3389/fphys.2017.01081

CYP1A1 Ile462Val Polymorphism Is Associated with Cervical Cancer Risk in Caucasians Not Asians: A Meta-Analysis

Li-Na Wang 1,2,†, Fen Wang 3,†, Jie Liu 2,4,†, Ying-Hui Jin 2,5, Cheng Fang 5,6, Xue-Qun Ren 2,4,*
PMCID: PMC5741838  PMID: 29326607

Abstract

Objective: Previous studies have reported that Ile462Val polymorphism in the gene Cytochrome P450 1A1 (CYP1A1) is associated with the risk of cervical cancer, but inconsistent results have emerged. Hence, we performed this updated and cumulative meta-analysis to ascertain a more accurate association between CYP1A1 Ile462Val polymorphism and risk of cervical cancer.

Methods: Studies involving the CYP1A1 Ile462Val polymorphism associated with cervical cancer risk were searched from the databases of PubMed, Scopus, ScienceDirect, and Chinese National Knowledge Infrastructure (CNKI). The strength of correlation was evaluated through calculating summary odds ratios (ORs) with the corresponding 95% confidence intervals (95% CIs). Subgroup analyses according to ethnicity, source of control and HWE were completed to further explore specific association between the polymorphism and the cancer risk.

Results: Altogether, 11 eligible case-control studies were ultimately encompassed into the current meta-analysis, with 1,932 patients and 2,039 healthy controls. The total analysis revealed a borderline relationship between CYP1A1 Ile462Val polymorphism and cervical cancer risk in general population. Interestingly, after subgroup analyses based on ethnicity and source of control, the polymorphism increased the susceptibility of cervical cancer in Caucasian (G vs. A: OR = 1.97, 95% CI = 1.24–3.13; GG vs. AA: OR = 3 .24, 95% CI = 1.24–8.46; GA vs. AA: OR = 1.62, 95% CI = 1.25–2.10; GA+GG vs. AA: OR = 1.68, 95% CI = 1.16–2.43; GG vs. AA+GA: OR = 2.73, 95% CI = 1.05–7.10) and population-based (G vs. A: OR = 1.49, 95% CI = 1.10–2.02; GA vs. AA: OR = 1.41, 95% CI = 1.20–1.67; GA+GG vs. AA: OR = 1.40, 95% CI = 1.19–1.64) groups.

Conclusion: The CYP1A1 Ile462Val polymorphism may enhance the susceptibility to cervical cancer in Caucasian females.

Keywords: CYP1A1, Ile462Val, cervical cancer, polymorphism, risk

Introduction

Cervical cancer is followed by breast cancer, which is the first common cancer among women all over the world (Denslow et al., 2012). Besides the onset of cervical cancer was aged 15–49 years in developing countries (Forouzanfar et al., 2011). Cervical cancer is a major threat to woman's health and quality of life, and is also the focal point and the difficulties for medical workers. Hence, to seek the risk factor and people who may be at high risk of cervical cancer for prevention is a significant and important work. As we know, smoking (Sood, 1991; Zeng et al., 2012) and human papillomavirus (HPV) infection (Patel et al., 2016) are the classical risk factor for cervical cancer. However, some women without smoking and HPV infection also got cervical cancer, why? That's might be other factors play a role in the onset of cervical cancer, such as genetic background.

Cytochrome P450 (CYP) gene family and susceptibility to many cancers has been the most widely studied (Rodriguez-Antona et al., 2010). CYP1A1 is belonged to CYP gene family1, subfamily A, polypeptide 1 and has two major functional nonsynonymous polymorphisms: MspI polymorphism m1 and Ile462Val polymorphism m2 (Sugawara et al., 2003). Ile462Val polymorphism is a heme-binding site due to the replacement of isoleucine (Ile) by valine (Val), which caused by G to A transition (A4889G) in exon 7 at codon 462, also called rs1048943 (https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1048943). There are five published meta-analyses directly or indirectly investigated the association between CYP1A1 Ile462Val polymorphism and risk of cervical cancer (Sergentanis et al., 2012; Yang et al., 2012; Wu et al., 2013; Qin et al., 2014; Wang et al., 2015), however, they obtained inconsistent results and with some deficiency (Table 1). For example, the meta-analysis performed by Yang et al. was conducted in 2012 involving ten case-control studies, and found that CYP1A1 Ile462Val polymorphism was associated with increased risk of cervical cancer in general populations. Besides, ethnic subgroup analyses showed a significant association was found in Caucasians but not in Asians (Yang et al., 2012). However, two publications (Geng et al., 2010; Shi et al., 2011) involved the same subjects were both included in above meta-analysis. Moreover, several new original studies (Abbas et al., 2014; Roszak et al., 2014; Li et al., 2016) on this topic were published since then. The recent meta-analysis by Wang et al. pooled the data of 8 case-control studies and indicated the CYP1A1 Ile462Val polymorphism might be a risk factor for cervical cancer (Wang et al., 2015). Since data extracted from two articles (Sugawara et al., 2003; Joseph et al., 2006) were repeatedly included in the meta-analysis, six case-control studies were actually included. Also, due to different inclusion criteria and uneven sample sizes, several meta-analyses (Wu et al., 2013; Qin et al., 2014) presented opposite conclusions. Additionally, subgroup analyses by ethnicity could not be performed due to limited number of studies.

Table 1.

Characteristics of previous published meta-analyses on CYP1A1 Ile462Val polymorphism and cervical cancer risk.

References Search databases End of search Included studies Study number Topic
Sergentanis et al., 2012 MEDLINE October, 2010 Sugawara et al., 2003; Joseph et al., 2006; Taskiran et al., 2006; Gutman et al., 2009 4 case–control studies MspI and Ile462Val polymorphisms and cervical cancer risk
Yang et al., 2012 PubMed, Embase, and CBM May, 2012 Sugawara et al., 2003; Huang et al., 2006; Joseph et al., 2006; Taskiran et al., 2006; Gutman et al., 2009; Zhang, 2009, 2011; Geng et al., 2010; Ding et al., 2011; Shi et al., 2011 10 case–control studies CYP1A1 Ile462Val polymorphism and cervical cancer risk
Wu et al., 2013 PubMed December 31, 2012 Sugawara et al., 2003; Joseph et al., 2006; Gutman et al., 2009 3 case–control studies MspI and Ile462Val polymorphisms and overall cancer risk
Qin et al., 2014 PubMed, ISI, and EMBASE April 15, 2013 Sugawara et al., 2003; Joseph et al., 2006; Taskiran et al., 2006; Gutman et al., 2009 4 case–control studies CYP1A1 Ile462Val polymorphism and cancer risk
Wang et al., 2015 PubMed and Embase June, 2014 Sugawara et al., 2003; Joseph et al., 2006; Taskiran et al., 2006; Gutman et al., 2009; Abbas et al., 2014; Roszak et al., 2014 8 case–control studies 42 SNPs with genetic risk for cervical cancer
Open in a new tab

Thus, we identified relevant published reports through a systematic search strategy, and performed this updated and cumulative meta-analysis to reappraise between CYP1A1 Ile462Val polymorphism and risk of cervical cancer. What's more, subgroup and sensitivity analyses were conducted to further ascertain such relationship.

Materials and methods

Ligibility criteria

Any study was considered eligible if it met all of the following criteria: (1) contain information investigated the association between CYP1A1 Ile462Val polymorphism and risk of cervical cancer; (2) as a cohort or case-control design; (3) both cases and controls were clearly diagnosed and all controls were healthy subjects or tissues; (4) included information that allowed for calculation of the odds ratios (ORs) and 95% confidence intervals (CIs). The study investigated the cervical dysplasia, cervical intraepithelial neoplasia (CIN), or cervical squamous intraepithelial lesions (CSIL) was excluded. If any publication involved the same subjects, we compared them according to the population, exposure, control, and study period and chosen the more comprehensive one.

Literature search

The PubMed, Scopus, ScienceDirect, and Chinese National Knowledge Infrastructure (CNKI) databases were searched for relevant studies that were published up to January 10, 2017. The search strategy included usage of the following key words: cervical, cervix, cancer, carcinoma, CYP1A1, cytochrome P-450, cytochrome P450, polymorphism, Ile462Val, A2455G, and rs1048943. Moreover, we also searched through the references which were cited in the included studies to obtain additional relevant studies. Two independent authors searched and evaluated the eligibility of all studies and any disagreements were resolved by discussion.

Data extraction

Two authors extracted the following data independently from all included studies: the last name of first author, year of publication, country of origin, ethnicity, sources of controls, sample sizes of cases and controls, genotype distribution in cases and controls, Hardy-Weinberg Equilibrium (HWE) for controls, and genotyping methods. If the HWE was not reported, we assessed it by the chi-square test and significance was set at P < 0.05 according to the genotype distribution in control. Disagreements were resolved by discussion.

Data analysis

All analyses were conducted using the Comprehensive Meta-Analysis v2.2 software (Zeng et al., 2016a,b). First, the heterogeneity was evaluated using the I2 test and Cochran Q test, both I2 < 50% and P > 0.1 was considered acceptance heterogeneity and the fixed-effect model was chosen to pool single study; otherwise, the random-effect model was used. Subgroup analyses according to ethnicity, source of control, and HWE were conducted. Five genetic models were used for overall and subgroup analyses: G vs. A, GG vs. AA, GA vs. AA, (GA+GG) vs. AA, and GG vs. (AA+GA). The odds ratio (OR) and its 95% confidence interval (95%CI) were used to evaluate the pooled effect size. Sensitivity analysis was performed to investigate the influence of a single study on overall analysis, and to test the robustness of overall results. Cumulative meta-analysis was carried out to observe the change when with sample sizes were enlarged (Pabalan, 2010; Rotondi and Bull, 2012). Publication bias was assessed by visual inspection of funnel plots and Egger's test.

Results

Study selection and characteristics

Figure 1 shows the study selection process. The primary search yielded potentially related publications and finally 11 case-control studies involving 1,932 patients and 2,039 healthy controls were included (Sugawara et al., 2003; Huang et al., 2006; Joseph et al., 2006; Gutman et al., 2009; Zhang, 2009, 2011; Ding et al., 2011; Shi et al., 2011; Abbas et al., 2014; Roszak et al., 2014; Li et al., 2016). Of these 11 case-control studies, four dealt with probands of Caucasian origin (Joseph et al., 2006; Gutman et al., 2009; Abbas et al., 2014; Roszak et al., 2014) and seven referred to Asian origin (Sugawara et al., 2003; Huang et al., 2006; Zhang, 2009, 2011; Ding et al., 2011; Shi et al., 2011; Li et al., 2016); five studies were out of Hardy Weinberg Equilibrium (HWE) (Huang et al., 2006; Zhang, 2009; Ding et al., 2011; Shi et al., 2011; Abbas et al., 2014). Table 2 lists the main characteristics of identified studies.

Figure 1.

Figure 1

Open in a new tab

Flow chart of study selection.

Table 2.

Main characteristics of studies included in this meta-analysis.

References Country (Ethnicity) Sample size Genotype distribution (Case) Genotype distribution (Control) Source of control Genotyping method HWE
Cases Controls AA AG GG A G AA AG GG A G
Sugawara et al., 2003 Japan (Asian) 75 31 48 27 0 123 27 21 10 0 52 10 PB PCR Yes
Huang et al., 2006 China (Asian) 113 113 36 62 1 134 64 14 95 1 123 97 HB PCR-RFLP No
Joseph et al., 2006 India (Caucasian) 147 165 91 45 11 227 67 136 26 3 298 32 PB PCR-RFLP Yes
Gutman et al., 2009 Israel (Caucasian) 43 123 29 14 0 72 14 85 31 5 201 41 PB PCR-RFLP Yes
Zhang, 2009 China (Asian) 50 30 14 26 10 54 34 17 7 6 41 19 HB PCR-RFLP No
Shi et al., 2011 China (Asian) 176 112 34 121 21 189 163 32 76 4 140 84 PB PCR-RFLP No
Ding et al., 2011 China (Asian) 280 280 72 129 79 273 287 83 100 97 266 294 PB PCR-RFLP No
Zhang, 2011 China (Asian) 32 114 14 13 3 41 19 34 51 17 119 85 HB PCR-RFLP Yes
Abbas et al., 2014 India (Caucasian) 200 208 110 84 6 304 96 114 65 2 347 69 PB PCR-RFLP No
Roszak et al., 2014 Poland (Caucasian) 456 495 415 41 0 871 82 466 29 0 961 29 PB PCR-RFLP Yes
Li et al., 2016 China (Asian) 360 368 199 141 20 539 181 217 135 16 569 167 PB PCR-Taqman Yes
Open in a new tab

PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; HWE, Hardy-Weinberg equilibrium.

Meta-analysis results

Table 3 demonstrates the results of overall and subgroup analyses. Overall, the association between CYP1A1 Ile462Val polymorphism and risk of cervical cancer was evaluated under five genetic models (G vs. A: OR = 1.27, 95% CI = 0.95–1.69, Figure 2; GG vs. AA: OR = 1.54, 95% CI = 0.87–2.74; GA vs. AA: OR = 1.27, 95% CI = 0.92–1.76; GA+GG vs. AA: OR = 1.25, 95% CI = 0.90–1.73; GG vs. AA+GA: OR = 1.31, 95% CI = 0.77–2.21), respectively. Sensitivity analysis indicated that the overall analysis was influenced only by Huang's study (Figure 3), which indicated that the results were robust. Moreover, cumulative meta-analysis was conducted by adding one study at a time in the order of publication year. The results showed that evidence of the effect of CYP1A1 Ile462Val polymorphism on cervical cancer incidence was stable during the cumulative meta-analysis, but the CIs became increasing narrower (Figure 4). In total analysis, the association between CYP1A1 Ile462Val polymorphism and cervical cancer incidence is borderline and may indicate a role of this variant.

Table 3.

Meta-analysis results on the relationship of CYP1A1 Ile462Val polymorphism with cervical cancer risk.

Total and subgroups Trails G vs. A GG vs. AA GA vs. AA (GA+GG) vs. AA GG vs. (AA+GA)
OR (95%CI) I2(%) OR (95%CI) I2(%) OR (95%CI) I2(%) OR (95%CI) I2(%) OR (95%CI) I2(%)
Total 11 1.27 (0.95–1.69) 81.67 1.54 (0.87–2.74) 54.99 1.27 (0.92–1.76) 72.99 1.25 (0.90–1.73) 75.05 1.31 (0.77–2.21) 52.36
ETHNICITY
Asian 7 1.00 (0.79–1.26) 58.5 1.29 (0.72–2.30) 51.69 1.08 (0.66–1.75) 78.88 1.04 (0.66–1.64) 78.07 0.92 (0.69–1.22) 44.89
Caucasian 4 1.97 (1.24–3.13) 75.81 3.24 (1.24–8.46) 42.09 1.62 (1.25–2.10) 22.1 1.68 (1.16–2.43) 50.26 2.73 (1.05–7.10) 36.39
SOURCE OF CONTROL
HB 3 0.76 (0.48–1.21) 50.72 0.92 (0.39–2.22) 35.54 0.85 (0.18–4.02) 89.44 0.77 (0.18–3.22) 89.18 0.80 (0.35–1.81) 0
PB 8 1.49 (1.10–2.02) 80.72 1.91 (0.94–3.87) 64.4 1.41 (1.20–1.67) 1.64 1.40 (1.19–1.64) 33.69 1.61 (0.79–3.28) 68.65
HWE
No 5 1.11 (0.79–1.56) 76.56 1.79 (0.79–4.06) 57.43 1.22 (0.63–2.34) 85 1.17 (0.63–2.15) 84.31 1.38 (0.65–2.96) 57
Yes 6 1.42 (0.87–2.33) 84.29 1.23 (0.40–3.74) 63.86 1.36 (0.97–1.91) 50.6 1.34 (0.91–1.98) 64.31 1.24 (0.49–3.14) 52.09
Open in a new tab

Figure 2.

Figure 2

Open in a new tab

Forest plot for the relationship between CYP1A1 Ile462Val polymorphism and cervical cancer risk under allele G vs. allele A genetic model.

Figure 3.

Figure 3

Open in a new tab

Sensitivity analysis results for removal of each included study under allele G vs. allele A genetic model.

Figure 4.

Figure 4

Open in a new tab

Cumulative meta-analysis of the association between CYP1A1 Ile462Val polymorphism and cervical cancer risk under allele G vs. allele A genetic model.

In the subgroup analysis for ethnicity, no significant association was found in Asians under any genetic models, but significantly increased risk was observed in Caucasians under all contrasts (G vs. A: OR = 1.97, 95% CI = 1.24–3.13; GG vs. AA: OR = 3.24, 95% CI = 1.24–8.46; GA vs. AA: OR = 1.62, 95% CI = 1.25–2.10; GA+GG vs. AA: OR = 1.68, 95% CI = 1.16–2.43; GG vs. AA+GA: OR = 2.73, 95% CI = 1.05–7.10). After stratified analysis by source of controls, significant results were found in population-based controls (G vs. A: OR = 1.49, 95% CI = 1.10–2.02; GA vs. AA: OR = 1.41, 95% CI = 1.20–1.67; GA+GG vs. AA: OR = 1.40, 95% CI = 1.19–1.64). No significant association existed in the studies conforming to HWE or deviating from HWE under all five genetic models (Table 3).

Publication bias

As shown in Figure 5, no obvious publication bias was found. The Egger's test also showed no evidence of publication bias (G vs. A: P = 0.68; GG vs. AA: P = 0.57; GA vs. AA: P = 0.92; GA+GG vs. AA: P = 0.81; GG vs. AA+GA: P = 0.26).

Figure 5.

Figure 5

Open in a new tab

Funnel plot of publication bias for CYP1A1 Ile462Val polymorphism.

Discussion

Cervical cancer is the second most common cancer among women worldwide, frequently occurring in developing countries in particular (Forouzanfar et al., 2011; Denslow et al., 2012). To date, the pathogenesis of cervical cancer has not been identified utterly, but a few risk factors have been confirmed, including human papilloma virus (HPV) infection, smoking, multiparity and long duration of oral contraceptive use (Zeng et al., 2012; Patel et al., 2016). Currently, the complex interaction of environmental and genetic factors is also proposed to possibly conduce to the occurrence of cervical cancer.

Cytochrome P450 1A1 (CYP1A1) is a member of the CYP1 family and participates in the metabolic activation of structurally diverse xenobiotics and endobiotics (Rodriguez-Antona et al., 2010). So far, numerous studies have been conducted on the association between CYP1A1 Ile462Val polymorphism and the susceptibility to cervical cancer, but the conclusions are not unanimous (Sugawara et al., 2003; Huang et al., 2006; Abbas et al., 2014). A few meta-analyses (Sergentanis et al., 2012; Yang et al., 2012; Wu et al., 2013; Qin et al., 2014; Wang et al., 2015) were also conducted to figure out the influence of CYP1A1 Ile462Val polymorphism on cervical cancer susceptibility. However, due to different inclusive criteria and uneven sample sizes, these reports presented different conclusions. Although most of them indicated that CYP1A1 Ile462Val polymorphism might be a risk factor for cervical cancer, the effects of the polymorphism on different ethnic groups were not fully clarified. Therefore, we conducted this cumulative meta-analysis to obtain accurate and up-to-date estimates of the association between the CYP1A1 Ile462Val polymorphism and cervical cancer susceptibility.

In the current meta-analysis, we incorporated 11 case-control studies involving 1,932 patients and 2,039 healthy controls to statistically discuss this issue. According to our inclusion criteria, the controls clearly diagnosed as healthy subjects or tissues were included and those investigated the cervical dysplasia, cervical intraepithelial neoplasia (CIN), or cervical squamous intraepithelial lesions (CSIL) were excluded. Thus, the study by Taskiran et al. was not included in this meta-analysis (Taskiran et al., 2006). After data syntheses, we found a borderline correlation of CYP1A1 Ile462Val polymorphism with the susceptibility to cervical cancer in total analysis. And the polymorphism significantly elevated the risk in Caucasian and population-based groups after subgroup analyses by ethnicity and source of control. Sensitivity analysis was conducted to evaluate the influence of individual study on overall analysis, which indicated that the overall results were robust. Furthermore, assessment of publication bias was confirmed by visual inspection of funnel plots and Egger's test, supporting that publication bias across the studies was negligible. Cumulative meta-analysis was also carried out to observe the change when with sample sizes were enlarged, and the CIs became increasing narrower. Recently, the relationships between some other polymorphisms and cervical cancer development were investigated, such as CYP1A1 MspI (rs4646903), COMT (rs4680), and CYP2E1 (rs3813867) polymorphisms. Importantly, a significant association between the MspI polymorphism and elevated cervical cancer risk was observed (Von et al., 2011; Matos et al., 2016). Studies suggest that Ile462Val polymorphism is in tight linkage disequilibrium with the MspI polymorphism, and these variant genotypes are associated with greater CYP1A1 activity or inducibility (Crofts et al., 1994; Ng et al., 2005). Thus, the borderline association between Ile462Val polymorphism and cervical cancer risk cannot be excluded and may indicate a role of this variant, which warrants further functional studies.

Despite certain advantages, there still were some limitations to be addressed. To begin with, the sample sizes of subgroup analyses were relatively small, which might affect the final results. Second, since meta-analysis is a secondary analysis (Zeng et al., 2015), the possible impacts of gene-gene and gene-environment interactions with this polymorphism on cervical cancer susceptibility were not evaluated due to insufficient information from original papers. Third, only studies published in English or Chinese language were included, some unpublished due to negative findings or other reasons and in other languages might be missed.

In summary, our meta-analysis outcomes revealed a borderline relationship between CYP1A1 Ile462Val polymorphism and cervical cancer risk in general population, and this polymorphism significantly increase the risk in Caucasian females. It provides an important theoretical basis to reveal the CYP1A1 Ile462Val polymorphism and the biological mechanism of developing cervical cancer, which may be helpful to predict the occurrence of cervical cancer in Caucasian females. Importantly, special attention should be paid upon the design of future studies, such as selection of subjects and adjustment of interfering factors so as to uncover any underlying mechanisms and distinct patterns. In view of the above mentioned restrictions, these results should be applied with prudence and further verified by large-scale and well-designed studies with various ethnic groups.

Author contributions

L-NW and X-QR designed this study; FW and Y-HJ searched databases and collected full-text papers; JL and CF extracted and analyzed data; L-NW, FW, and JL wrote the manuscript, X-QR reviewed the manuscript.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Abbas M., Srivastava K., Imran M., Banerjee M. (2014). Association of CYP1A1 gene variants rs4646903 (T>C) and rs1048943 (A>G) with cervical cancer in a North Indian population. Eur. J. Obstet. Gynecol. Reprod. Biol. 176, 68–74. 10.1016/j.ejogrb.2014.02.036 [DOI] [PubMed] [Google Scholar]
  2. Crofts F., Taioli E., Trachman J., Cosma G. N., Currie D., Toniolo P., et al. (1994). Functional significance of different human CYP1A1 genotypes. Carcinogenesis 15, 2961–2963. 10.1093/carcin/15.12.2961 [DOI] [PubMed] [Google Scholar]
  3. Denslow S. A., Knop G., Klaus C., Brewer N. T., Rao C., Smith J. S. (2012). Burden of invasive cervical cancer in North Carolina. Prev. Med. 54, 3–4. 10.1016/j.ypmed.2012.01.020 [DOI] [PubMed] [Google Scholar]
  4. Ding F. Y., Ma G. F., Song X. H., Shi W. H., Lan J. Y., Yu H. Y. (2011). Relationship between CYP1A1 gene polymorphism and genetic susceptibility of cervical carcinoma. Jiangsu Med. J. 37, 2562–2564. [Google Scholar]
  5. Forouzanfar M. H., Foreman K. J., Delossantos A. M., Lozano R., Lopez A. D., Murray C. J., et al. (2011). Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 378, 1461–1484. 10.1016/S0140-6736(11)61351-2 [DOI] [PubMed] [Google Scholar]
  6. Geng J., Shi Y. R., Wang H., Qin R. (2010). Research of cytochrome P450 1A1 Ile/Val polymorphism and genetic susceptibility in cervical cancer. J. Bengbu Med. Coll. 35, 762–767. [Google Scholar]
  7. Gutman G., Morad T., Peleg B., Peretz C., Bar-Am A., Safra T., et al. (2009). CYP1A1 and CYP2D6 gene polymorphisms in Israeli Jewish women with cervical cancer. Int. J. Gynecol. Cancer 19, 1300–1302. 10.1111/IGC.0b013e3181b9fa5d [DOI] [PubMed] [Google Scholar]
  8. Huang Y. K., Hsieh H. C., Sun J. A., Chao C. F., Huang R. L., Lai H. C., et al. (2006). Genetic polymorphisms of phase I and phase II xenobiotic enzymes in human papillomavirus related lesion and cancer of the uterine cervix. Tzu Chi Med. J. 18, 267-274+328. [Google Scholar]
  9. Joseph T., Chacko P., Wesley R., Jayaprakash P. G., James F. V., Pillai M. R. (2006). Germline genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes in Indian cervical cancer: associations with tumor progression, age and human papillomavirus infection. Gynecol. Oncol. 101, 411–417. 10.1016/j.ygyno.2005.10.033 [DOI] [PubMed] [Google Scholar]
  10. Li S., Li G., Kong F., Liu Z., Li N., Li Y., et al. (2016). The association of CYP1A1 gene with cervical cancer and additional SNP-SNP interaction in chinese women. J. Clin. Lab. Anal. 30, 1220–1225. 10.1002/jcla.22006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Matos A., Castelao C., Pereira da Silva A., Alho I., Bicho M., Medeiros R., et al. (2016). Epistatic Interaction of CYP1A1 and COMT Polymorphisms In Cervical Cancer. Oxid. Med. Cell. Longev. 2016:2769804. 10.1155/2016/2769804 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ng D. P., Tan K. W., Zhao B., Seow A. (2005). CYP1A1 polymorphisms and risk of lung cancer in non-smoking Chinese women: influence of environmental tobacco smoke exposure and GSTM1/T1 genetic variation. Cancer Causes Control 16, 399–405. 10.1007/s10552-004-5476-0 [DOI] [PubMed] [Google Scholar]
  13. Pabalan N. A. (2010). Meta-analysis in cancer genetics. Asian Pac. J. Cancer Prev. 11, 33–38. [PubMed] [Google Scholar]
  14. Patel H., Jeve Y. B., Sherman S. M., Moss E. L. (2016). Knowledge of human papillomavirus and the human papillomavirus vaccine in European adolescents: a systematic review. Sex. Transm. Infect. 92, 474–479. 10.1136/sextrans-2015-052341 [DOI] [PubMed] [Google Scholar]
  15. Qin J., Zhang J. X., Li X. P., Wu B. Q., Chen G. B., He X. F. (2014). Association between the CYP1A1 A2455G polymorphism and risk of cancer: evidence from 272 case-control studies. Tumour Biol. 35, 3363–3376. 10.1007/s13277-013-1443-2 [DOI] [PubMed] [Google Scholar]
  16. Rodriguez-Antona C., Gomez A., Karlgren M., Sim S. C., Ingelman-Sundberg M. (2010). Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum. Genet. 127, 1–17. 10.1007/s00439-009-0748-0 [DOI] [PubMed] [Google Scholar]
  17. Roszak A., Lianeri M., Sowinska A., Jagodzinski P. P. (2014). CYP1A1 Ile462Val polymorphism as a risk factor in cervical cancer development in the Polish population. Mol. Diagn. Ther. 18, 445–450. 10.1007/s40291-014-0095-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Rotondi M. A., Bull S. B. (2012). Cumulative meta-analysis for genetic association: when is a new study worthwhile? Hum. Hered. 74, 61–70. 10.1159/000345604 [DOI] [PubMed] [Google Scholar]
  19. Sergentanis T. N., Economopoulos K. P., Choussein S., Vlahos N. F. (2012). Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and cervical cancer risk: a meta-analysis. Mol. Biol. Rep. 39, 6647–6654. 10.1007/s11033-012-1470-x [DOI] [PubMed] [Google Scholar]
  20. Shi Y. R., Geng J., Cheng L. Q., Wang H., Zhang Y. G. (2011). Association of Cytochrome P450 1A1 gene polymorphisms with cervical cancer. Fudan Univ. J. Med. Sci. 38, 428–431. 10.3969/j.issn.1672-8467.2011.05.010 [DOI] [Google Scholar]
  21. Sood A. K. (1991). Cigarette smoking and cervical cancer: meta-analysis and critical review of recent studies. Am. J. Prev. Med. 7, 208–213. [PubMed] [Google Scholar]
  22. Sugawara T., Nomura E., Sagawa T., Sakuragi N., Fujimoto S. (2003). CYP1A1 polymorphism and risk of gynecological malignancy in Japan. Int. J. Gynecol. Cancer 13, 785–790. 10.1111/j.1525-1438.2003.13607.x [DOI] [PubMed] [Google Scholar]
  23. Taskiran C., Aktas D., Yigit-Celik N., Alikasifoglu M., Yuce K., Tunçbilek E., et al. (2006). CYP1A1 gene polymorphism as a risk factor for cervical intraepithelial neoplasia and invasive cervical cancer. Gynecol. Oncol. 101, 503–506. 10.1016/j.ygyno.2005.11.018 [DOI] [PubMed] [Google Scholar]
  24. Von K. H., Bergmann T., Schuetz M., Schiller U., Stanke J., Hoffmann C., et al. (2011). Analysis of 4 single-nucleotide polymorphisms in relation to cervical dysplasia and cancer development using a high-throughput ligation-detection reaction procedure. Int. J. Gynecol. Cancer 21, 1664–1671. 10.1097/IGC.0b013e31822b6299 [DOI] [PubMed] [Google Scholar]
  25. Wang S., Sun H., Jia Y., Tang F., Zhou H., Li X., et al. (2015). Association of 42 SNPs with genetic risk for cervical cancer: an extensive meta-analysis. BMC Med. Genet. 16:25. 10.1186/s12881-015-0168-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wu B., Liu K., Huang H., Yuan J., Yuan W., Wang S., et al. (2013). MspI and Ile462Val polymorphisms in CYP1A1 and overall cancer risk: a meta-analysis. PLoS ONE 8:e85166. 10.1371/journal.pone.0085166 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Yang S., Jia C., Zhu H., Han S. (2012). CYP1A1 Ile462Val polymorphism and cervical cancer: evidence from a meta-analysis. Tumour Biol. 33, 2265–2272. 10.1007/s13277-012-0488-y [DOI] [PubMed] [Google Scholar]
  28. Zeng X. T., Leng W. D., Lam Y. Y., Yan B. P., Wei X. M., Weng H., et al. (2016a). Periodontal disease and carotid atherosclerosis: a meta-analysis of 17,330 participants. Int. J. Cardiol. 203, 1044–1051. 10.1016/j.ijcard.2015.11.092 [DOI] [PubMed] [Google Scholar]
  29. Zeng X. T., Xia L. Y., Zhang Y. G., Li S., Leng W. D., Kwong J. S. (2016b). Periodontal disease and incident lung cancer risk: a meta-analysis of cohort studies. J. Periodontol. 87, 1158–1164. 10.1902/jop.2016.150597 [DOI] [PubMed] [Google Scholar]
  30. Zeng X. T., Xiong P. A., Wang F., Li C. Y., Yao J., Guo Y. (2012). Passive smoking and cervical cancer risk: a meta-analysis based on 3,230 cases and 2,982 controls. Asian Pac. J. Cancer Prev. 13, 2687–2693. 10.7314/APJCP.2012.13.6.2687 [DOI] [PubMed] [Google Scholar]
  31. Zeng X., Zhang Y., Kwong J. S., Zhang C., Li S., Sun F., et al. (2015). The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J. Evid. Based Med. 8, 2–10. 10.1111/jebm.12141 [DOI] [PubMed] [Google Scholar]
  32. Zhang S. H. (2009). Polymorphisms of Cyp1a1 Gene and HPV Infection of Cervical Squamous Carcinoma. Master of Medicine Master's thesis, Taishan Medical University. [Google Scholar]
  33. Zhang X. (2011). P450 1A1 gene polymorphism and cervical cancer I leVal Correlation. Jilin Med. J. 32, 419–420. 10.3969/j.issn.1004-0412.2011.03.001 [DOI] [Google Scholar]

Articles from Frontiers in Physiology are provided here courtesy of Frontiers Media SA

RESOURCES